Who owns Ryaltris?
Ryaltris is owned by Glenmark (India, NSE: GLENMARK).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Glenmark Pharmaceuticals Limited Integrated Annual Report FY2026, 13 August 2026. Last checked .
Key facts
- Current owner
- Glenmark Pharmaceuticals Limited reported
- Owner HQ
- 🇮🇳 India, Mumbai
- Origin
- 🇮🇳 India
- Category
- Healthcare & pharma › Drug makers › Pharmaceuticals
- Parent ticker
- NSE: GLENMARK BSE: 532296
- Last verified
- · 1 sources
About Ryaltris
Ryaltris is Glenmark's nasal spray for the symptoms of seasonal allergic rhinitis and Glenmark's first global branded specialty drug, approved by the US FDA in 2022. The FY2026 annual report says it is sold in 56 markets including China, grew secondary sales by more than 50%, and that Glenmark now distributes it directly in the US.
Ownership timeline of Ryaltris
Where Ryaltris sits in Glenmark
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Glenmark ownership tree →
See the full Glenmark brand portfolio (9) →
Other brands owned by Glenmark
Glenmark controls 9 brands on Brandtree, 4 of them in healthcare & pharma.
Also in healthcare & pharma
Other brands in pharmaceuticals, and who owns them
The 27 brands in pharmaceuticals on Brandtree belong to 10 owners. The largest is Teva, with 4; Glenmark has 4.
About the owner: Glenmark
Glenmark is a publicly listed company headquartered in Mumbai, India, founded in 1977. Brandtree records 9 brands under its control, and it is listed as NSE: GLENMARK and BSE: 532296.
Glenmark is a Mumbai drugmaker whose founder, Gracias Saldanha, laid the company's foundation stone in 1977. Its FY2026 annual report describes branded, generic and over-the-counter businesses in India, North America, Europe and emerging markets, plus an innovation arm, Ichnos Glenmark Innovation. In 2024 it completed the sale of its 75% stake in its API maker, Glenmark Life Sciences (now Alivus Life Sciences), to Nirma Limited.
🇮🇳 Ryaltris and other Indian brands
Brandtree records a controlling owner for 279 brands that began in India. 9 of them (3%) are now controlled by a company headquartered in another country; Ryaltris is not one of them.
- Bharat Serums and Vaccines — Mankind Pharma 🇮🇳
- Foracort — Cipla 🇮🇳
- Nise — Dr. Reddy's 🇮🇳
- Niva Bupa — Niva Bupa 🇮🇳
- Star Health Insurance — Star Health 🇮🇳
- 8PM — Radico Khaitan 🇮🇳
Official recalls involving Ryaltris products
1 recall notice from government regulators matched to Ryaltris. Each applies to the specific products, sizes and lot codes named in the notice, not to every product sold under the name.
- Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mcg per spray, 240 Metered Sprays/bottle, 29 g net fill weight, Distr. by… — FDA, · Class II
Reason given: Defective Delivery System: The dip tube is clogged causing the spray not to work.
Recalling firm: Glenmark Pharmaceuticals Inc., USA
Matched automatically from FDA, USDA FSIS, UK Food Standards Agency and CPSC records only when the recalling firm corresponds to this ownership record and, for a brand, the brand name appears in the product description. Check the linked notice for exact products and lots. Method.
Frequently asked questions
Who is the parent company of Ryaltris?
The parent company of Ryaltris is Glenmark, a publicly listed company headquartered in India.
Is Ryaltris Indian?
Yes. Ryaltris originated in India and its owner, Glenmark, is also headquartered in India.
Is Ryaltris still owned by Glenmark?
Yes. As of 21 October 2026, Ryaltris is still owned by Glenmark. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Glenmark Pharmaceuticals Limited Integrated Annual Report FY2026 — Glenmark Pharmaceuticals Limited, Annual report, published 13 August 2026; retrieved 21 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.